{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for mycophenolic root_references_citation in Reference Text / Citation (approximate match)
Status:
Possibly Marketed Outside US
Source:
NCT01686698: Phase 4 Interventional Completed Cirrhosis
(2013)
Source URL:
First approved in 2019
Source:
Provad by TMIG Inc
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 346
(2018)
Source URL:
First approved in 2018
Source:
21 CFR 346
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04487613: Phase 4 Interventional Completed Postpartum Women
(2021)
Source URL:
First approved in 2017
Source:
MIRACLE SOS GOLD by Ddoruroo Co., Ltd.
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2016)
Source URL:
First approved in 2016
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 352
(2015)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
21 CFR 347
(2021)
Source URL:
First approved in 2015
Source:
moisturizing daily by KAS Direct LLC dba BabyGanics
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT01927094: Phase 4 Interventional Completed Acute Diarrhea
(2012)
Source URL:
First approved in 2015
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M019
(2024)
Source URL:
First approved in 2013
Source:
21 CFR 358H
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
NCT04645407: Phase 4 Interventional Completed Novel Coronavirus Pneumonia
(2020)
Source URL:
First approved in 2011
Source:
21 CFR 333A
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
Vitamin C 10 % by PURETEK CORPORATION
(2024)
Source URL:
First approved in 2009
Source:
21 CFR 352
Source URL:
Class:
STRUCTURALLY DIVERSE